New study aims to cut opioid use after knee replacement with targeted nerve blocks

NCT ID NCT07677215

First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time

Summary

This trial compares three ways to manage pain after total knee replacement. All patients receive standard nerve blocks, but some also get an anti-inflammatory drug (dexamethasone) or a combination of dexamethasone and a sedative (dexmedetomidine). The goal is to see which approach reduces the need for opioids and improves recovery. The study involves 120 adults aged 60 to 100 undergoing knee replacement.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Ropivacaine, dexamethasone, dexmedetomidine
What this could lead to
If successful, this could identify a safer, more effective pain management approach for knee replacement patients, reducing opioid dependence and speeding recovery.
What could go wrong
This is a single-center trial with 120 participants, so results may not apply broadly. Adding drugs like dexmedetomidine may increase side effects such as low blood pressure or sedation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for KNEE OSTEOARTHRITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Poznan University of Medical Sciences

    Poznan, 62-701, Poland

  • The John Paul II Catholic University of Lublin

    Lublin, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.